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the cellular content of AzI increased transiently after 
induction of cell proliferation by diluting cells in fresh 
medium. Inhibition of polyamine biosynthesis induced 
an even larger increase in the cellular AzI content, which 
remained significantly elevated during the 7-day experi-
mental period. However, this increase was not a conse-
quence of changes in cell cycle progression, as demon-
strated by flow cytometry. Instead, the increase appeared 
to correlate with the cellular depletion of polyamines. 
Moreover, induced overexpression of AzI resulted in an 
increased cell proliferation with a concomitant increase 
in ODC activity and putrescine content. During mitosis, 
AzI1 was localised in a pattern that resembled that of the 
two centrosomes, confirming earlier observations. Taken 
together, the results indicate that AzI fulfils an essential 
regulatory function in polyamine homeostasis and cell 
proliferation.
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AzI  Antizyme inhibitor
BrdUrd  Bromodeoxyuridine
DFMO  Difluoromethylornithine
ECL  Enhanced chemiluminescence
FITC  Fluorescein isothiocyanate
LI  Labelling index
ODC  Ornithine decarboxylase
PBS  Phosphate-buffered saline
PI  Propidium iodide
RMzero  Relative movement zero
uCC  Upstream conserved coding region
Abstract The polyamines are important for a variety 
of cellular functions, including cell growth. Their intra-
cellular concentrations are controlled by a complex net-
work of regulatory mechanisms, in which antizyme (Az) 
has a key role. Az reduces the cellular polyamine content 
by down-regulating both the enzyme catalysing polyam-
ine biosynthesis, ornithine decarboxylase (ODC), and 
the uptake of polyamines. The activity of Az is repressed 
by the binding of a protein, named Az inhibitor (AzI), 
which is an enzymatically inactive homologue of ODC. 
Two forms of AzI have been described: AzI1, which is 
ubiquitous, and AzI2 which is expressed in brain and 
testis. In the present study, we have investigated the role 
of AzI1 in polyamine homeostasis and cell proliferation 
in breast cancer cells. The results obtained showed that 
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Introduction
Polyamines are recognised as necessary growth factors in 
all cells, including cancer cells (Wallace et al. 2003; Gerner 
and Meyskens 2004; Nowotarski et al. 2013). Perturbation 
of intracellular polyamine content in mammalian cells has 
dramatic effects on cell proliferation and cell death/apop-
tosis. Thus, a complex of elaborate mechanisms, affecting 
synthesis, degradation as well as membrane transport, has 
evolved for the control of polyamine homeostasis (Pers-
son 2009; Pegg and Casero 2011). Ornithine decarboxylase 
(ODC) is a key regulatory protein catalysing the first and 
rate-limiting step in polyamine biosynthesis. This enzyme 
is strictly regulated by antizyme (Az), which binds to ODC 
with a high affinity at the monomeric level, inhibiting the 
formation of the active ODC homodimer and targeting it 
for ubiquitin-independent degradation by the 26S protea-
some (Kahana 2009; Murai et al. 2011).
In addition, Az inhibits the cellular uptake of extracel-
lular polyamines (Mitchell et al. 1994; Suzuki et al. 1994). 
The cellular content of Az is partly regulated by polyamines, 
which stimulate its synthesis by a unique mechanism 
involving ribosomal frame-shifting (Rom and Kahana 
1994; Matsufuji et al. 1995). At least three different mam-
malian isoforms of Az (Az1–Az3) have been identified, of 
which Az1 and Az2 are ubiquitously expressed, whereas 
Az3 is testis-specific (Kahana 2009). All three Az isoforms 
are capable of inhibiting ODC activity and polyamine 
uptake, but only Az1 and Az2 can target ODC for degrada-
tion (Kahana 2009).
In addition to Az, cells contain another protein with a 
putative role in polyamine homeostasis. This protein was 
first discovered in rat liver by the potential to reactivate Az-
inhibited ODC and was thus given the name of Az inhibi-
tor (AzI) (Fujita et al. 1982). AzI, which is an enzymati-
cally inactive homologue of ODC, binds to Az with higher 
affinity than does ODC and consequently releases ODC 
from its inactive ODC-Az complex (Fujita et al. 1982). By 
binding to Az, AzI also prevents the effects of Az on ODC 
degradation and cellular uptake of polyamines (Kahana 
2009; Murai et al. 2011). Keren-Paz et al. (2006) demon-
strated that NIH3T3 cells overexpressing AzI had increased 
ODC activity and polyamine uptake, and exhibited 
improved cell proliferation. Moreover, these cells gave 
rise to tumours when injected into nude mice (Keren-Paz 
et al. 2006), whereas knockdown of AzI using siRNA or 
shRNA decreased cell proliferation both in vitro and in 
vivo (Choi et al. 2005; Keren-Paz et al. 2006; Olsen et al. 
2012). Mutant mice with both AzI alleles disrupted, died 
close to birth and displayed abnormal liver morphology 
and perturbed polyamine homeostasis (Tang et al. 2009). 
Interestingly, AzI has also been shown to be up-regulated 
in a number of human cancers (Jung et al. 2000; Schaner 
et al. 2003; van Duin et al. 2005; Chin et al. 2007; Olsen 
and Zetter 2011).
In spite of its putative role in polyamine homeostasis and 
its cell proliferation-promoting effects, information on the 
regulation and cellular function of AzI is relatively sparse. 
Nevertheless, a close correlation between cell prolifera-
tion, ODC and AzI has been demonstrated (Murakami et al. 
1989; Nilsson et al. 2000; Murakami et al. 2009). Results 
indicate that AzI may have other functions besides being 
involved in polyamine homeostasis. Zetter and colleagues 
reported that AzI reduced the turnover of cyclin D, as well 
as induced centrosome overduplication (Kim et al. 2006; 
Mangold et al. 2008). A co-localisation of Az1 and AzI to 
the centrosome during mitosis was confirmed by Murakami 
et al. (2009). In addition to the ubiquitously present AzI, a 
closely related protein, termed AzI2, is expressed in brain 
and testis (Pitkanen et al. 2001; Lopez-Contreras et al. 
2006). Thus, the first AzI discovered is sometimes referred 
to as AzI1. Similar to AzI1, AzI2 neutralises the effects of 
Az on ODC and the cellular uptake of polyamines (Lopez-
Contreras et al. 2008; Snapir et al. 2008). In addition, Kan-
erva et al. (2010) presented results indicating that AzI2 is 
involved in the regulation of vesicular transport within the 
cell.
In the present study, we investigated the role of AzI1 
(referred to as AzI) in polyamine homeostasis and cell pro-
liferation in breast cancer cells. The results show that AzI 
expression varied in relation to cell proliferation and poly-
amine content. Moreover, induced overexpression of AzI 
resulted in an increased cell proliferation with a concomi-
tant increase in ODC activity and putrescine content. AzI 
was shown to be localised in a centrosomal pattern during 
mitosis, confirming earlier observations of a co-localisation 
of AzI with centrosomes (Mangold et al. 2008; Murakami 
et al. 2009).
Materials and methods
Cell culture medium components were purchased from 
Biochrom, Berlin, Germany. Tissue culture plastics were 
acquired from Nunc, Roskilde, Denmark. Phosphate-
buffered saline (PBS: 8 g/L NaCl, 0.2 g/L KCl, 1.15 g/L 
Na2HPO4, 0.2 g/L KH2PO4, pH 7.3) was purchased from 
Oxoid Ltd., Basingstoke, Hampshire, UK. Nonidet P-40 
was purchased from VWR, Lund, Sweden. Insulin and pro-
pidium iodide (PI) were obtained from Sigma, Stockholm, 
Sweden. Dimethyl sulphoxide (DMSO) was acquired 
from Merck KGaA, Darmstadt, Germany. l-[1-14C] Orni-
thine (1.9 GBq/mmol) was purchased from New England 
Nuclear Du Pont, Scandinavia AB, Stockholm, Sweden. 
Bromodeoxyuridine (BrdUrd) and the primary monoclo-
nal antibody against BrdUrd (Clone: Bu20a), as well as the 
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secondary fluorescein isothiocyanate (FITC)-conjugated 
antibody and the secondary horseradish peroxidase-con-
jugated goat anti-mouse IgG antibody, were all purchased 
from DAKO, Glostrup, Denmark. Hybond enhanced 
chemiluminescence (ECL) nitrocellulose membrane and 
ECL™ Advance Blotting Detection Kit (Amersham Bio-
sciences) were purchased from GE Healthcare, Uppsala, 
Sweden. Geneticin and all components of the NuPAGE 
Novex Pre-Cast Gel System used for Western blot were 
obtained from Invitrogen Corporation, Carlsbad, CA, USA. 
The antibody against β-actin was purchased from Abcam, 
Cambridge, UK. The monoclonal antibody against rat AzI1 
was kindly provided by Dr. Senya Matsufuji and Dr. Yas-
uku Murakami, Tokyo, Japan. Gene Pulser Cyvettes (0.4 
and 0.1 cm) were purchased from Bio-Rad, Hercules, CA, 
USA. The mammalian expression vector pCl-neo was pur-
chased from Promega Corporation, Madison, WI, USA. 
The Nucleo Spin Extract Kit was obtained from Clonetech 
Laboratories, Inc., Mountainview, CA, USA. The agarose 
gels were obtained from Bio-Rad Laboratories, Hercules, 
CA, USA. The Genelute HP plasmid midi-prep kit was 
purchased from Sigma-Aldrich Sweden AB, Stockholm, 
Sweden. Restriction enzymes and T4 DNA ligase were 
purchased from Fermentas GMBH, Helsingborg, Sweden. 
The oligos for PCR were obtained from TAG, Copenhagen, 
Denmark. Difluoromethylornithine (DFMO) was purchased 
from Ilex-Oncology, San Antonio, Texas, USA. SAM486A 
was a kind gift from Novartis, Basel, Switzerland.
Drug stock solutions
Stock solutions of SAM486A (2 mM), aminoguani-
dine (AG, 50 mM), putrescine (50 mM) and spermidine 
(50 mM) were made in PBS. DFMO was dissolved in Milli-
pore water to obtain a concentration of 0.5 M after adjusting 
pH to 7.2. All solutions were sterile-filtered and used in 
the experiments at final concentrations of: SAM486A 
(20 μM), AG (1 mM), putrescine (100 μM), spermidine 
(50 μM) and DFMO (1 mM).
Cell culture
The human breast carcinoma cell line JIMT-1 (ACC589) was 
purchased from the German Collection of Microorganisms 
and Cell Cultures, DSMZ (Braunschweig, Germany) and 
was cultured in DMEM/Ham’s F12 medium supplemented 
with 10 % foetal bovine serum, non-essential amino acids 
(1 mM), insulin (10 µg/ml), penicillin (100 U/ml) and 
streptomycin (100 µg/ml). The human breast carcinoma 
cell line MCF-7 (HTB22) was obtained from the Ameri-
can Type Culture Collection (Manassas, VA, USA) and was 
cultured in RPMI 1640 medium supplemented with 10 % 
foetal bovine serum, non-essential amino acids (1 mM), 
insulin (10 µg/ml), penicillin (100 U/ml) and streptomycin 
(100 µg/ml). Both cell lines were cultured as monolayers at 
37 °C in a humidified incubator with 5 % CO2 in air. The 
JIMT-1 cell line, having a doubling time of approximately 
24 h, was sub-cultured twice a week, while the MCF-7 cell 
line, with a doubling time of approximately 34 h, was sub-
cultured once a week. In all experiments, plateau phase 
cells were reseeded to a lower cell density (30,000 cells/
cm2). The cells were seeded in the absence or presence of 
DFMO, SAM486A, DFMO/putrescine or DFMO/sper-
midine. In experiments using spermidine, AG was added 
to inhibit any activity of polyamine oxidases present in 
the bovine serum. The cells were harvested by trypsinisa-
tion and the cell number was determined by counting in a 
hemocytometer at times indicated in the figures. The cells 
were pelleted and stored at −80 °C until further analysis.
ODC activity assay
The cells were sonicated in ice-cold 0.1 M Tris–HCl (pH 
7.5) containing 0.1 mM EDTA and 2.5 mM dithiothrei-
tol. The ODC activity was determined by measuring the 
release of [14C] CO2 from carboxyl-labelled l-ornithine, in 
the presence of saturating levels of pyridoxal 5-phosphate 
(0.1 mM) and l-ornithine (0.2 mM) (Jänne and Williams-
Ashman 1971).
Polyamine analysis
Chromatographic separation and quantitative determination 
of the polyamines in cell extracts in 0.2 M perchloric acid 
were carried out using a HPLC (Hewlett Packard 1100) 
with θ-phthaldialdehyde as the reagent essentially as previ-
ously described (Seiler and Knödgen 1980).
Cell cycle progression analysis
Cells were seeded in the absence or presence of DFMO 
and harvested by trypsinisation every second hour for up 
to 24 h after seeding. Thirty minutes before harvesting, 
BrdUrd (5 µM) was added to the medium of the cells. The 
cells were collected and fixed in ice-cold 70 % ethanol 
and stored at −20 °C until further analysis. At the time of 
analysis, BrdUrd incorporated into DNA was labelled with 
primary BrdUrd antibodies followed by secondary FITC-
conjugated antibodies, and DNA was stained with PI, as 
recently described (Silva et al. 2013). The labelled cells 
were analysed by flow cytometry using an Ortho Cyto-
ron Absolute flow cytometer (Ortho Diagnostic Systems, 
Raritan, NJ, USA). The MultiCycle® software program 
(Phoenix Flow Systems, CA, USA) was used for evalua-
tion of the data with respect to DNA and BrdUrd contents. 
Cell cycle progression during the 24 h after seeding was 
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monitored by following changes in relative movement zero 
(RMzero) and labelling index (LI) (Fredlund and Oredsson 
1996).
Western blot analysis of AzI
The cells were diluted in sample buffer (62.5 mM 
Tris–HCl, pH 6.8, 20 % glycerol, 2 % SDS, 5 % 
β-mercaptoethanol and 0.5 % bromophenol blue) and 
sonicated, followed by immediate boiling for 6 min. The 
samples were stored at −20 °C until analysis. Aliquots con-
taining 50,000 or 100,000 cells were loaded and separated 
on 4–12 % acrylamide Bis–Tris gels (Invitrogen) using the 
Xcell Sure Lock™ Mini-Cell System (Invitrogen). The 
separated proteins were transferred to nitrocellulose mem-
branes using the iBlot™ Dry Blotting System (Invitrogen). 
Thereafter, the membranes were blocked in 5 % non-fat 
dry milk in PBS-T (PBS containing 0.05 % Tween 20) and 
incubated overnight with the primary antibody against rat 
AzI (1:50,000) at 4 °C. Following washing in PBS-T, the 
membranes were incubated with the secondary horseradish 
peroxidase-conjugated goat anti-mouse IgG antibody 
(1:20,000) in PBS-T for 1 h at room temperature. The 
bands were detected with the ECL™ Advance Blotting 
Detection Kit. The ChemiDoc XRS system and the Quan-
tity One software (both from Bio-Rad Laboratories Inc., 
Hercules, CA, USA) were used for imaging and data analy-
sis. Actin was used as a loading control.
Stable transfection of AzI
The coding region of human AzI1 was subcloned from 
pcDNA3.1-AzI (kindly provided by Leif Andersson, Hel-
sinki) into the mammalian expression vector pCI-neo. 
Exponentially growing JIMT-1 and MCF-7 cells were 
transfected with the pCI-neo/AzI construct or the pCI-neo 
empty vector using a Gene Pulser® II (Bio-Rad, CA, USA). 
Stable transfectants were selected by addition of geneticin 
(0.5 mg/ml) to the cell culture medium.
Immunofluorescence microscopy
Cells were cultured on sterile poly-l-lysine-coated glass 
slides for 48 h. After fixation in 3.7 % paraformaldehyde 
(in PBS) for 15 min at room temperature and subsequent 
washing in PBS, the slides were blocked in 5 % non-fat 
dry milk in PBS-T for 1 h at room temperature. The cells 
were incubated with the primary AzI antibody diluted 
1:10,000 in PBS-T overnight at 4 °C. After washing, the 
cells were incubated for 1 h with the Alexa Fluor 488 Goat 
Anti-mouse antibody (Invitrogen) (diluted 1:500 in PBS-
T), at room temperature. Slides were counterstained with 
bisbenzimide and finally washed in PBS before mounting. 
Fluorescence-labelled cells were photographed using an 
Olympus/Nikon epifluorescence microscope (Olympus 
Optical Co. Ltd., Japan) equipped with a digital camera 
(Nikon Imaging Japan Inc., Japan). The final images shown 
were obtained by overlaying AzI- and bisbenzimide-stained 
pictures using Adobe Photoshop 8.0.1 (Adobe Systems 
Incorporated, San Jose, California, USA).
Statistical analysis
Values are expressed as mean ± SEM. Students’ t test was 
used for statistical evaluation and p < 0.05 was considered 
as significant.
Results
Effects of DFMO on polyamine homeostasis
Initially, we analysed the effects of DFMO on JIMT-1 
breast cancer cells. Treatment with DFMO significantly 
reduced the proliferation of JIMT-1 cells seeded in 
fresh medium (Fig. 1a). The late effect of DFMO on cell 
proliferation was preceded by changes in the polyamine 
metabolism, seen as early as 24 h after start of treatment 
(Fig. 1). ODC activity (which was transiently increased 
after reseeding) and intracellular polyamine content were 
decreased markedly by treatment with DFMO (Fig. 1b, e). 
In contrast to putrescine, which was depleted entirely after 
24 h of DFMO treatment, the spermidine concentration 
continued to decrease to about 10 % of the control value at 
48 h of treatment, whereas spermine was not affected sig-
nificantly by DFMO treatment (Fig. 1e). Interestingly, the 
cellular content of AzI increased transiently after reseeding 
the cells in fresh medium (Fig. 1c, d). In parallel with the 
early changes in polyamine metabolism, the AzI level had 
increased dramatically after 24 h of DFMO treatment and 
remained elevated during the entire treatment cycle of 
168 h, although a 50 % reduction was observed from day 
5 (Fig. 1c, d).
Effects of DFMO on cell cycle progression
The AzI content has been shown to vary during the cell 
cycle, with peaks in the G1 and G2/M phases (Murakami 
et al. 2009). Since the AzI content was increased signifi-
cantly in JIMT-1 cells as early as 24 h of DFMO treat-
ment, we decided to investigate whether this increase was 
a consequence of DFMO affecting the cell cycle progres-
sion. The cells used for seeding were partly synchronised 
and approximately 80 % (results not shown) were in G0/G1 
phase (plateau phase cells). Small treatment-induced effects 
on the partially synchronised cell cycle progression may 
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result in large changes in levels of proteins that vary during 
the cell cycle, like AzI. Thus, we determined whether 
DFMO provoked any changes in the cell cycle progression 
during the first 24 h of treatment. Cell cycle progression 
was followed by analyses of RMzero and LI after labelling 
DNA with BrdUrd (Fig. 2a, b).
RMzero is a measure of the distribution of BrdUrd-
labelled cells in S phase (Begg et al. 1985; Fredlund and 
Oredsson 1996). When BrdUrd-labelled cells are distributed 
uniformly in S phase, RMzero is 0.5. RMzero is below 0.5 
when the BrdUrd-labelled cells are in early S phase and 
above 0.5 when the cells are in late S phase. LI is a measure 
of the number of cells that have incorporated BrdUrd in 
proportion to the total number of cells examined. Figure 2a 
shows changes in RMzero after seeding. RMzero was above 
0.5 at the first sampling time (i.e. 2 h after seeding) and 
then it increased to a maximum at 8 h after seeding. During 
this time, the LI was 10 % (Fig. 2b). Taken together, these 
data imply that the 10 % of cells in S phase were located 
mainly at the end of S phase at the time of seeding. The 
rapid drop in RMzero between 8 and 16 h after seeding is 
caused by the massive inflow of cells from G1 phase into S 
phase, due to the partially synchronous proliferation of the 
cells (Fig. 2a). This is reflected in a large increase in LI dur-
ing the same time period (Fig. 2b). DFMO treatment had 
no effect on this early cell cycle progression (Fig. 2a, b). 
Thus, the increased AzI level found after 24 h of treatment 
(Fig. 1c, d) was not caused by a DFMO-induced effect 
on early cell cycle progression. Instead, it is conceivable 
that the induction of AzI after treatment with DFMO was 
related to the decrease in cellular putrescine and/or spermi-
dine content (Fig. 2e).
Fig. 1  Long-term effects of DFMO on cell proliferation, ODC activ-
ity, AzI level and polyamine content in JIMT-1 cells. Cells were 
seeded in the absence or presence of 1 mM DFMO (DF). a The cells 
were harvested for analyses every 24 h for up to 168 h by trypsini-
sation and the cell number was determined by using a hemocytom-
eter. Cell pellets were prepared and used for various analyses. b 
ODC activity was determined by a radiometric assay. c and d AzI 
was determined and quantified by Western blot (d) and the data from 
three experiments were densitometrically scanned and presented 
as relative AzI expression (c). e Putrescine, spermidine and sper-
mine contents were determined by HPLC. Values are mean ± SEM 
(n = 3–7). When not visible, the SEM bars are covered by the sym-
bols. *p < 0.05; **p < 0.01; ***p < 0.001 (compared to controls)
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Feedback control of AzI
An extensive analysis of AzI expression during the first 
24 h of DFMO treatment showed that the AzI level was 
significantly increased after 22 h of treatment (Fig. 2c, 
d), whereas the putrescine and spermidine levels were 
decreased at 14 and 20 h, respectively, after seeding in the 
presence of DFMO (Fig. 2e). To determine whether the 
induced increase in the cellular AzI level was due to the 
decrease in cellular putrescine and/or spermidine content 
Fig. 2  Short-term effects of DFMO on cell proliferation, AzI level 
and polyamine content in JIMT-1 cells. Cells were seeded in the 
absence or presence of 1 mM DFMO and sampled for various analy-
ses every other hour for the first 24 h after seeding. A DNA—bromo-
deoxyuridine (BrdUrd) method was used to follow cell cycle progres-
sion after seeding. Thirty minutes prior to sampling, 5 µM BrdUrd was 
added to the medium of the cells. The cells were harvested and fixed 
in 70 % ethanol. After labelling DNA with PI and the incorporated 
BrdUrd with antibodies, the cells were analysed by flow cytometry. 
Cell cycle progression was monitored by following changes in RMzero 
(a) and LI (b). AzI was determined by Western blot (d) and the data 
from three experiments were densitometrically scanned and pre-
sented as relative AzI expression (c). Putrescine, spermidine and sper-
mine levels were determined by HPLC (e). Values are mean ± SEM 
(n = 4–5). When not visible, the SEM bars are covered by the sym-
bols. *p < 0.05; **p < 0.01 (compared to controls)
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caused by DFMO treatment, we examined if addition of 
putrescine or spermidine reversed the effect of the inhibitor 
on the AzI level seen after 24 h of treatment. As expected, 
addition of putrescine or spermidine to the cells treated 
with DFMO restored the cellular content of putrescine and/
or spermidine to control or above control values (Fig. 3d). 
Moreover, the addition of putrescine or spermidine pre-
vented the DFMO-induced increase in cellular AzI content, 
(Fig. 3a, b). AG, which was added to the growth medium 
to prevent extracellular oxidation of spermidine by serum 
amine oxidases, had no effect on AzI expression, ODC 
activity or polyamine content per se (Fig. 3). The effect 
of SAM486A on the cellular AzI level was also analysed. 
SAM486A is an inhibitor of S-adenosylmethionine decar-
boxylase, which together with ODC catalyses the key steps 
in the biosynthesis of polyamines (Pegg 2009). Treatment 
with SAM486A for 24 h resulted in an increased cellu-
lar level of AzI, which was similar to that observed after 
treatment with DFMO (Fig. 3a, b). The cellular putres-
cine content was also markedly increased, whereas the 
spermidine and particularly, the spermine content were 
decreased (Fig. 3d). Thus, the cellular expression of AzI 
appeared to be at least partly regulated by the polyamine 
pools. A decrease in the polyamine content thus resulted in 
an increase in AzI, which presumably caused an increase 
in the ODC level (due to the interaction of AzI with Az). 
Fig. 3  Regulation of AzI by polyamines in JIMT-1 cells. Cells were 
seeded in the absence of compound (control) or in the presence of 
1 mM DFMO, 20 μM SAM486A, 1 mM aminoguanidine (AG), or 
1 mM DFMO (DF) and 100 μM putrescine (put), or 1 mM DFMO, 
50 μM spermidine (Spd) and 1 mM AG and then sampled at 24 h 
after seeding. AzI was determined by Western blot (a) and the data 
from three experiments were scanned using densitometry and pre-
sented as relative AzI expression (b). ODC activity was determined 
by a radiometric assay (c) and putrescine, spermidine and spermine 
contents (d) were determined by HPLC. Values are mean ± SEM 
(n = 3–6). When not visible, the SEM bars are covered by the sym-
bols. *p < 0.05; **p < 0.01; ***p < 0.001 (compared to controls)
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Consequently, AzI is an important regulatory protein in the 
feedback control of polyamine homeostasis.
Effects of AzI overexpression
We next investigated the effect of perturbed AzI expression 
on polyamine homeostasis and cell proliferation. Two breast 
cancer cell lines, JIMT-1 and MCF-7, were transfected with an 
expression vector containing the coding region of human AzI1 
and stable transfectants were isolated. As shown in Fig. 4a,b, 
both cell lines transfected with the AzI-containing vector 
exhibited a marked increase in the expression of AzI compared 
to the cells transfected with the empty vector. Interestingly, 
both cell lines expressing a high level of AzI also exhibited an 
increased cell proliferation over 96 h in culture, as compared 
to the control cells (Fig. 4c). Increased AzI expression was 
also associated with an increase in ODC activity in the trans-
fected cells 48 h after seeding (Fig. 4d). This was seen clearly 
in the AzI-expressing MCF-7 cells, where a more than four-
fold increase in ODC activity was observed compared to the 
control cells 48 h after seeding (Fig. 4d). The cellular content 
of putrescine increased markedly; whereas that of spermine 
decreased in the cells expressing high levels of AzI compared 
to the control cells (Fig. 4e). Expression of AzI did not affect 
cellular spermidine content (Fig. 4e).
Cellular localisation of AzI
It has previously been reported that cellular localisation 
of AzI varies during the cell cycle, with a cytoplasmic 
Fig. 4  Effect of stable transfection with AzI in MCF-7 and JIMT-1 
cells. MCF-7 and JIMT-1 breast cancer cells were stably trans-
fected with empty vector (pCl-neo) or vector containing AzI (pCl-
neo + AzI). AzI was determined by Western blot (a) and the data 
from three experiments were scanned using densitometry and pre-
sented as relative AzI expression (b). Proliferation of the cells was 
compared in growth curve experiments where the cell number was 
determined by counting in a hemocytometer (c). ODC activity was 
determined by a radiometric assay (d) and putrescine, spermidine 
and spermine contents (e) were determined by HPLC. Values are 
mean ± SEM (n = 3–6). When not visible, the SEM bars are covered 
by the symbols. *p < 0.05; **p < 0.01; ***p < 0.001 (compared to 
controls)
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localisation during interphase and a centrosomal locali-
sation during mitosis, thereby indicating a role for AzI in 
the mitotic process (Mangold et al. 2008; Murakami et al. 
2009). In the present study, we determined the intracellular 
localisation of AzI in JIMT-1 cells 48 h after seeding, using 
immunofluorescence microscopy (Fig. 5). In early mito-
sis, before chromosomal alignment and centrosomal sepa-
ration, AzI was found in the cytoplasm and in the central 
part of the nuclear area (Fig. 5a). In metaphase/anaphase, 
AzI was localised in a pattern that resembled the two cen-
trosomes having chromosomes in between (Fig. 5b).
Discussion
As shown in the present study, the cellular level of AzI 
increased during the exponential growth of JIMT-1 cells. 
The increase probably reflects a rapid induction of AzI 
transcription after reseeding the cells in fresh medium. 
Nilsson et al. (2000) have demonstrated a rapid increase 
in AzI mRNA in mouse fibroblasts after growth stimula-
tion by serum. Since binding of ODC to Az inhibits ODC 
activity, as well as stimulates its degradation, it is highly 
likely that the early increase in ODC activity seen in the 
JIMT-1 cells after seeding in fresh medium can be partly 
explained by a stabilisation/reactivation of the ODC protein 
caused by the sequestering of Az by AzI (Murakami et al. 
1989; Nilsson et al. 2000). ODC activity started to decrease 
after 24 h, whereas the AzI level remained elevated for 
96 h, after reseeding the cells in fresh medium. The ODC 
level (and activity) is dependent on a variety of factors 
which affect synthesis and degradation (e.g. ODC synthesis 
rate, levels of Az and AzI) and thus the ODC activity may 
decrease even though the level of AzI remains elevated.
We also demonstrate that DFMO inhibits the polyamine 
biosynthetic pathway, while simultaneously increasing 
the AzI level in exponentially growing breast cancer cells, 
indicating a feedback control of AzI by the polyamines. 
Since the AzI level has been reported to fluctuate within 
the cell cycle with peaks during early G1 and G2/M phases 
(Murakami et al. 2009), the observed increase in AzI level 
after DFMO treatment could also be due to an accumula-
tion of cells in a specific phase (e.g. G1) of the cell cycle 
caused by the ODC inhibitor. However, it was clear that the 
cell cycle progression was not affected by DFMO during 
the first 24 h of treatment, whereas the induction of AzI was 
observed as early as 16 h after start of treatment. Instead, 
the increase in AzI caused by DFMO appeared to corre-
late with a decrease in putrescine and/or spermidine levels 
in the cells. This was further supported by the reversible 
effect of putrescine and spermidine on DFMO-induced 
increase of AzI. Moreover, treatment with SAM486A 
resulted in a similar increase in cellular AzI content as that 
observed after DFMO treatment. However, the effects of 
the two inhibitors on cellular polyamine content differed. 
DFMO reduced putrescine and spermidine levels, whereas 
SAM486A reduced spermidine and spermine levels along 
with an increase in putrescine content. Thus, it would 
appear that the negative control of AzI is not exerted by a 
single polyamine. Instead, all of the three polyamines may 
have the capability to down-regulate AzI, although with 
different potencies. Murakami et al. (2009) have previously 
shown that the expression of AzI is negatively regulated by 
any of the polyamines in HTC cells.
Ivanov et al. (2008) demonstrated that all available 
sequences of vertebrate AzI mRNAs contain an upstream 
conserved coding region (uCC) of about 50 codons. The 
uCC lacks an in-frame AUG codon, but contains a con-
served AUU near the 5′ end, which might serve as an ini-
tiation codon for the uCC. Using a luciferase reporter 
assay, Ivanov et al. (2008) were able to show that the uCC 
of mouse AzI mRNA mediates polyamine-induced repres-
sion of the downstream main open reading frame. In 
Fig. 5  Localisation of AzI during mitosis in JIMT-1 cells. Cells were 
seeded on poly-l-lysine-coated glass slides and fixed in parafor- 
maldehyde. They were then stained with the primary AzI antibody 
and the secondary Alexa Fluor 488 antibody (green fluorescence) and 
DNA was stained with bisbenzimide (blue fluorescence). (a) Early 
mitosis. (b) Metaphase/anaphase. Size of bar in fluorescence micros-
copy images: 20 µm
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spermidine-supplemented cells, the expression of the main 
open reading frame was repressed 6.5-fold compared with 
that of polyamine-depleted (DFMO-treated) cells. How-
ever, this repression was essentially lost when the putative 
initiation codon of the uCC was mutated from AUU to a 
non-initiating UUU codon. Moreover, mutating the last 
10 sense codons of the uCC gave similar results, eliminat-
ing polyamine-induced repression of main open reading 
frame translation. The results obtained in the present study 
together with those of Murakami et al. (2009), confirm that 
the expression of AzI in mammalian cells is regulated by 
polyamines. It is highly likely that this regulation occurs, 
at least partly, at the translational level by the mechanism 
suggested by Ivanov et al. (2008). AzI is reported to have a 
short half-life (Bercovich and Kahana 2004) and thus any 
change in the synthesis rate will result rapidly in a change 
in the level of the AzI protein. Murakami et al. (2009) were 
able to show that putrescine down-regulated AzI mainly at 
the translation level in HTC cells. Murakami et al. (2014) 
recently demonstrated that polyamines may also regulate 
AzI expression by affecting the transcription as well as the 
splicing pattern of the mRNA. They showed that polyam-
ines, besides reducing the transcription of full-length AzI1 
mRNA, actually increased the level of a splice variant with 
a premature termination codon (coding for an AzI lacking 
almost two-thirds of the C-terminal region). In addition, 
polyamine depletion achieved after treatment with DFMO 
gave the opposite effect.
Increased levels of ODC and polyamines are distinctive 
features of rapid cell proliferation and of numerous forms 
of cancer (Wallace et al. 2003; Pegg 2006). ODC may be 
considered as a possible oncogene and overexpression of 
this enzyme has been demonstrated to induce cellular trans-
formation in a variety of systems (Wallace et al. 2003; Pegg 
2006; Shantz and Levin 2007). Thus, polyamine homeostasis 
is highly regulated and AzI appears to play an important role 
in this regulation. As shown in the present study, overexpres-
sion of AzI resulted in an increased cell proliferation, along 
with elevated levels of ODC and putrescine. Interestingly, 
the marked increase in ODC activity seen in the AzI-trans-
fected cells during exponential growth (48 h after seeding) 
was not correlated with any major changes in polyamine lev-
els, indicating that polyamine homeostasis is dependent on 
a variety of factors other than ODC activity [e.g. substrates 
for synthesis, other enzymes in the polyamine pathway (syn-
thetic or degradative), cellular uptake or efflux of polyam-
ines]. The increase in ODC activity was most likely related 
to a stabilisation of the enzyme due to the binding of Az 
to AzI. Keren-Paz et al. (2006) demonstrated that NIH3T3 
mouse fibroblasts overexpressing AzI had elevated ODC 
and polyamine levels, and proliferated faster than control 
cells. Similar findings were obtained by Kim et al. (2006) 
using NIH3T3 cells and AT2.1 rat prostate carcinoma cells 
overproducing AzI. Keren-Paz et al. (2006) also demon-
strated that AzI-overexpressing cells grew in the presence 
of low concentrations of serum, formed colonies in soft 
agar and gave rise to tumours when injected into nude mice, 
which all are attributes of transformed cells. In addition, AzI 
has been found to be up-regulated in a large number of can-
cers and thus may be regarded as a putative oncogene (Jung 
et al. 2000; Schaner et al. 2003; van Duin et al. 2005; Chin 
et al. 2007; Olsen and Zetter 2011). Conversely, silencing of 
AzI expression has been shown to reduce cell proliferation 
in vitro (Choi et al. 2005; Keren-Paz et al. 2006; Kim et al. 
2006; Olsen et al. 2012), as well as repress tumour growth in 
vivo (Olsen et al. 2012). The effects of AzI most likely occur 
through the binding to Az and suppression of its functions. 
In addition to affecting the turnover of ODC, Az has been 
reported to stimulate the degradation of proteins important 
for cell cycling as well as centrosome duplication (Newman 
et al. 2004; Kasbek et al. 2010; Dulloo et al. 2010).
The results of the present study support the interesting 
observation of a centrosomal localisation of AzI during 
mitosis previously reported by Mangold et al. (2008) and 
Murakami et al. (2009). Also Az has been shown to be 
co-localised with the centrosome during mitosis (Mangold 
et al. 2008; Murakami et al. 2009). Interestingly, altera-
tions in the AzI/Az ratio caused abnormalities in numbers 
of centrosomes in the cell, which further indicates a role 
for Az (and AzI) in centrosomal duplication (Mangold et al. 
2008). It is conceivable that Az regulates the turnover of 
an essential centrosomal component. In fact, Az has been 
reported to stimulate the degradation of Aurora-A, which is 
a key protein in centrosome amplification (Lim and Gopa-
lan 2007). However, more work is needed to identify the 
exact functions of Az and AzI in mitosis.
In conclusion, our findings strongly indicate that AzI 
plays essential roles in polyamine homeostasis and cell 
proliferation.
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